Acumen Pharmaceuticals (ABOS) Competitors $1.56 -0.12 (-6.85%) As of 12:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. ARCT, BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, and AMRNShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Arcturus Therapeutics (ARCT), Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Arcturus Therapeutics Benitec Biopharma Gossamer Bio COMPASS Pathways Prothena Altimmune Aura Biosciences Cartesian Therapeutics Capricor Therapeutics Amarin Acumen Pharmaceuticals (NASDAQ:ABOS) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, ABOS or ARCT? Acumen Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Which has stronger earnings & valuation, ABOS or ARCT? Arcturus Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$102.33M-$1.94-0.81Arcturus Therapeutics$131.27M3.07-$80.94M-$2.53-5.88 Is ABOS or ARCT more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -58.24% -46.53% Arcturus Therapeutics -47.47%-27.41%-19.01% Do insiders and institutionals have more ownership in ABOS or ARCT? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ABOS or ARCT? Acumen Pharmaceuticals presently has a consensus price target of $6.33, indicating a potential upside of 304.69%. Arcturus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 263.24%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media refer more to ABOS or ARCT? In the previous week, Arcturus Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 1 mentions for Arcturus Therapeutics and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 equaled Arcturus Therapeutics'average media sentiment score. Company Overall Sentiment Acumen Pharmaceuticals Neutral Arcturus Therapeutics Neutral SummaryArcturus Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.19M$3.06B$5.68B$9.50BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-0.8020.9727.9520.00Price / SalesN/A250.27397.1083.19Price / CashN/A41.9636.1958.45Price / Book0.528.288.665.83Net Income-$102.33M-$55.19M$3.24B$258.39M7 Day Performance5.74%5.06%3.33%2.30%1 Month Performance24.21%17.64%10.84%12.42%1 Year Performance-51.40%7.00%35.32%21.16% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals2.3491 of 5 stars$1.57-6.8%$6.33+304.7%-52.5%$94.19MN/A-0.8020ARCTArcturus Therapeutics1.7983 of 5 stars$13.31-3.4%$54.00+305.7%-34.6%$360.98M$131.27M-5.26180BNTCBenitec Biopharma1.6721 of 5 stars$13.25+3.7%$23.83+79.9%+31.8%$347.81M$80K-8.7720GOSSGossamer Bio3.5433 of 5 stars$1.53+12.5%$8.25+439.2%+74.8%$347.77M$114.70M-6.65180High Trading VolumeCMPSCOMPASS Pathways1.9847 of 5 stars$3.71+1.1%$17.00+358.2%-36.5%$347.11MN/A-1.86120Upcoming EarningsPRTAProthena3.9499 of 5 stars$6.43+0.5%$31.50+389.9%-72.2%$346.11M$137.94M-3.09130News CoverageALTAltimmune2.0057 of 5 stars$4.26+2.9%$18.20+327.2%-33.3%$345.53M$20K-3.3850AURAAura Biosciences2.7151 of 5 stars$6.75+5.5%$22.00+225.9%-25.8%$339.32MN/A-3.5550Positive NewsRNACCartesian Therapeutics1.6985 of 5 stars$13.06-2.0%$40.00+206.3%-21.3%$338.91M$38.91M-0.2564News CoverageCAPRCapricor Therapeutics2.6432 of 5 stars$7.39-3.3%$22.56+205.2%+42.7%$337.58M$22.27M-5.20101AMRNAmarin0.3072 of 5 stars$16.10-4.9%$12.00-25.5%-0.7%$333.43M$228.61M-4.42360Upcoming Earnings Related Companies and Tools Related Companies ARCT Competitors BNTC Competitors GOSS Competitors CMPS Competitors PRTA Competitors ALT Competitors AURA Competitors RNAC Competitors CAPR Competitors AMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts